"uuid:ID","description","rationale","label","id","instanceType","name"
"a7ea2070-0a22-420d-bf56-1f0346fd67b9","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign_1","StudyDesign","Study Design 1"
